Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.
Vibalogics, a virotherapy contract development and manufacturing organization (CDMO) focused on the production of live viruses and viral vectors, has announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany.
The CDMO has picked up Arranta Bio and Vibalogics in a two-pronged bid to beef up in biologics. Arranta specializes in microbiome therapeutic products and mRNA clinical production, while Vibalogics focuses on the production of oncolytic viruses, viral vaccines and gene therapies. The latter company also provides process and analytical development, manufacturing, testing and fill-finish services.
Vibalogics, a global contract development and manufacturing organization (CDMO) specializing in the production of oncolytic viruses, viral vectors, and vaccine virotherapy products, has made key senior U.S.-based hires to the global leadership team.
A German CDMO specializing in viral manufacturing is expanding its operations in Europe by building out an existing plant — and soon, it will be its own landlord, too.
Invests an additional $50 million to further expand cGMP manufacturing capacity for viral vectors.
Vibalogics, a global contract development and manufacturing organization (CDMO), initiated the first stage of a $50 million investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical virotherapy manufacturing capacity.
As Vibalogics looks to carve out a manufacturing foothold in the U.S., the CDMO is turning back to its native Germany to pump another $50 million into viral vector production.
As Vibalogics looks to carve out a manufacturing foothold in the U.S., the CDMO is turning back to its native Germany to pump another $50 million into viral vector production.
Vibalogics, a global contract development and manufacturing organization (CDMO) specializing in the production of virotherapy products, has appointed Mike DiMeo to the executive board as CFO, while Judith Adair McCorry has joined as vice president of quality, and Hao (Max) Qian as head of process sciences.